http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
항암치료와 통합암치료 병용으로 호전된 전이성 난소 및 자궁내막암 환자 1례
진용재,신광순,하지용,Jin, Yong Jae,Shin, Kwang Soon,Ha, Jee Yong 대한암한의학회 2014 大韓癌韓醫學會誌 Vol.19 No.1
This report is aimed to investigate the effect of Integrative Medicine Therapy (IMT) in treating metastasized ovary and endometrial cancer. A 51-year-old woman who was diagnosed double primary ovarian and endometrial cancer in 2009. The patient was treated with Laparoscopic Assisted Vaginal Hysterectomy (LAVH), Bilateral Salpingo Oophorectomy (BSO) Pelvic Lymph Node Dissection (PLND), adjuvant chemotherapy till Sep. in 2013. But metastases to Rt. External Iliac artery, Aortocaval area Lymph Nodes, Liver(caudate lobe), Rt. Buttock subcutaneous area, Lt. Gastric Area Lymph Nodes were found. Finally, the patient decided to be treated by IMT including Abnoba Viscum, Vitamin C, herbal medication and pharmacopuncture combined with chemotherapy. The efficacy was evaluated with Positron Emission Tomography and Computed Tomography (PET-CT) and Abdomen Computed Tomography (CT). The metastatic tumor in liver was disappeared and Rt. external iliac artery, aortocaval area Lymph Nodes, Rt. buttock subcutaneous area were also decreased after 6 months treatment. These results suggest that IMT may have a potential role for metastatic cancer.
카페시타빈과 통합의학 프로그램 치료 병용을 통해 호전된 진행성 유방암 1례
진용재,신광순,하지용,Jin, Yong Jae,Shin, Kwang Soon,Ha, Jee Yong 대한암한의학회 2014 大韓癌韓醫學會誌 Vol.19 No.1
This report is aimed to investigate the effect of Integrative Medicine Therapy (IMT) in treating breast cancer metastasized to several portion. A 55-year-old woman who was diagnosed breast cancer and treated by breast conservation surgery (BCS) IN 2002. (pT2M0N0), adjuvant chemotherapy and radiotherapy till Jan. in 2013. But cancer had metastasized to sacrum (2009), liver (2012) and ribs (2013). Finally cause of several side effects of Xeloda(neuralgia and vommiting), she gave up to be treated by Xeloda and started to receive IMT including Abnoba Viscum, Vitamin C therapy Xeloda again, Korean herbal medicine and pharmacopuncture from Jul. in 2013. The effect was evaluated with Positron Emission Tomography and Computed Tomography (PET-CT) and Abdomen Computed Tomography (CT). The metastatic tumor in liver was disappeared and cancers to ribs, their size decreased after 12 months and pain of sacrum maintained VAS 2 continually. These results suggest that IMT is a therapeutic method to treat metastatic tumor originated from breast cancer.
시장 국면별 공적 연기금 해외주식 자산군의 액티브 포트폴리오 전략
진용재,노상윤 한국재무관리학회 2023 財務管理硏究 Vol.40 No.6
본 연구는 공적 기금운용 조직들의 일반적인 포트폴리오 전략에 대한 패러다임 전환을 시도하였다. 이를 위해 본 연구는 다음과 같은 몇 가지 가정을 설정하였다. 공적 기금운용 조직은 향후 예상되는 특정 시장 국면별로 해외주식 자산군의 액티브 포트폴리오를 사전적으로 구성한다. 이때 투자 섹터들의 과거 유사 국면 하의 펀드들의 수익-위험 특성 변화를 반영한 최적 투자 비중을 사전에 체계적으로 설정한다. 그래서 만약 공적 기금운용 조직이 월간 자산배분 계획을 수립할 때, 다음 월에 특정 시장 국면이 예상되면, 사전적인 리밸런싱(rebalancing)을 할 수 있는 일정 규모의 액티브 포트폴리오를 운용한다. 본 연구는 이러한 가정하에 액티브 포트폴리오 운용 전략의 필요성과 기대효과를 제시해 보았다. 주요 연구 결과는 다음과 같다. 첫째, 시장 급등 국면(HUR, MUR)과 정상 위험(NR) 국면이 예상될 때, 이를 반영하여 사전적으로 리밸런싱한 액티브 포트폴리오는 정적 포트폴리오(ALL)를 유지하는 것보다 더 높은 위험조정 성과를 얻을 수 있을 것이다. 둘째, 일정 수준 이상의 시장 급락 국면(MDR)이 예상될 때, 과거 하락 국면의 주요 펀드들의 수익-위험 정보에 기초한 액티브 포트폴리오로 리밸런싱하면, 비록 감수할 위험 수준은 다소 높아질 수 있지만, 손실 규모가 대폭 축소되어 유효한 수익률 방어 전략을 수립할 수 있다. 셋째, 세계 경제 위기와 같은 극단적인 시장 급락(HDR) 국면이 예상될 때는 과거 수익-위험 특성에 기초한 포트폴리오 효과는 기대할 수 없다. This study attempted to change the paradigm of the general portfolio strategy of public fund management organizations. For this purpose, this study set several assumptions as follows. Public fund management organizations proactively construct active portfolios of overseas stock asset classes for each specific market regime expected in the future. At this time, the optimal investment proportion is systematically set in advance, reflecting changes in the return-risk profiles of funds under similar past regimes of investment market. Therefore, when a public fund management organization establishes a monthly asset allocation plan, if a specific market situation is expected in the next month, it operates a certain size of active portfolio that can perform preliminary rebalancing. This study presented the necessity and expected effects of an active portfolio management strategy under these assumptions. The main research results are as follows: First, when market surge regimes (HUR, MUR) and normal risk (NR) regimes are expected, an active portfolio that is rebalanced in advance to reflect this will be able to achieve higher risk adjustment performance than maintaining a static portfolio (ALL). Second, when a market plunge regime (MDR) above a certain level is expected, rebalancing to an active portfolio based on the return-risk profiles of major funds in past downturns may reduce the amount of loss, although the level of risk to be taken may be somewhat higher. It is greatly reduced, allowing an effective rate of return defense strategy to be established. Third, when an extreme market plunge regime (HDR) is expected, such as the global economic crisis, portfolio effects based on past return-risk profiles cannot be expected.
구본강,진용재,박상준,김천호 한국생체재료학회 2011 생체재료학회지 Vol.15 No.1
A biosensor is an analytical device which converts a biological response into an electrical signal. Recently, conducting polymers have received great attention in the development of biosensors. Conducting polymer is emerging materials with potential for biosensors because of their chemical sensitivity and biocompatibility. The conducting polymers are known to endow with abundance special features, which allow them to act as superior materials for immobilization of biomolecules and rapid response time for the fabrication of efficient biosensors. Conducting polymer, such as films,nanowires, as sensing platforms for application are also summarized in electrochemical and field effect transistor (FET)biosensor.
Pembrolizumab과 통합의학치료로 호전된 뇌전이 동반 말기 비소세포성 폐암 환자 1례
서한길,진용재,송미화,김인태,박지혜,정준석,조성규,신광순,Seo, Han Gil,Jin, Yong Jae,Song, Mi Hwa,Kim, In Tae,Park, Ji Hye,Jung, Jun Suk,Cho, Sung Kyoo,Shin, Kwang Soon 대한암한의학회 2018 大韓癌韓醫學會誌 Vol.23 No.2
Objective: The purpose of this study is to report the case of a patient with non-small cell lung cancer (NSCLC) with Programmed cell death protein 1 (PD-1) mutation treated by Integrative Medicine Therapy (IMT). Methods: A patient with metastatic NSCLC received pembrolizumab 200mg intravenously for every 3 weeks from July 2017. Repeat cycle every 3 weeks since July 2017. The patient has been treated with Integrative Medicine Therapy (IMT) since December 2016. The tumor size was measured by computed tomography (CT) and magnetic resonance imaging(MRI). Adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: After combined treatment, the extent of proximal portion of primary tumor in the left lower lobe was decreased and disease status was stable radiologically. No evidence of newly developed metastatic lesions in the brain since May 2017. The patient did not experience any adverse event according to NCI-CTCAE ver. 5.0. Conclusion: This case study suggests that Integrative Medicine Therapy (IMT) may contribute to tumor response, in conjunction with Pembrolizumab on the treatment of patients with NSCLC.